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Background: Deregulation of microRNA (miRNA) transcript levels has been observed in many types of tumors
including osteosarcoma. Molecular pathways regulated by differentially expressed miRNAs may contribute to the
heterogeneous tumor behaviors observed in naturally occurring cancers. Thus, tumor-associated miRNA expression
may provide informative biomarkers for disease outcome and metastatic potential in osteosarcoma patients. We
showed previously that clusters of miRNAs at the 14q32 locus are downregulated in human osteosarcoma.
Methods: Human and canine osteosarcoma patient’s samples with clinical follow-up data were used in this study.
We used bioinformatics and comparative genomics approaches to identify miRNA based prognostic biomarkers in
osteosarcoma. Kaplan-Meier survival curves and Whitney Mann U tests were conducted for validating the statistical
significance.
Results: Here we show that an inverse correlation exists between aggressive tumor behavior (increased metastatic
potential and accelerated time to death) and the residual expression of 14q32 miRNAs (using miR-382 as a
representative of 14q32 miRNAs) in a series of clinically annotated samples from human osteosarcoma patients. We
also show a comparable decrease in expression of orthologous 14q32 miRNAs in canine osteosarcoma samples,
with conservation of the inverse correlation between aggressive behavior and expression of orthologous miRNA
miR-134 and miR-544.
Conclusions: We conclude that downregulation of 14q32 miRNA expression is an evolutionarily conserved
mechanism that contributes to the biological behavior of osteosarcoma, and that quantification of representative
transcripts from this family, such as miR-382, miR-134, and miR-544, provide prognostic and predictive markers that
can assist in the management of patients with this disease.
Keywords: Bone neoplasm, Prognosis, Integrative analysis, Osteosarcoma, 14q32 miRNAsBackground
Osteosarcoma is the most common primary bone tumor
and predominantly affects children and adolescents [1,2].
The impact of osteosarcoma on patients, families, care-
givers, and the extended community (e.g., the sociological
impact on their peers) is disproportionate to the numbers
affected both due to morbidity and years of life lost. Due
to the infrequent occurrence as well as the heterogeneous* Correspondence: subree@umn.edu
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reproduction in any medium, provided the ornature of osteosarcoma in humans, the molecular under-
standing of this disease has progressed slowly as compared
to other cancer types. However, the occurrence of an
orthologous disease in dogs provides an opportunity to
surmount some of these challenges.
In contrast to humans, osteosarcoma is relatively com-
mon in dogs (estimated at >10,000 cases per year), with
exquisite breed predilection. Osteosarcoma arises spon-
taneously in dogs, and its biology is similar to the human
disease both anatomically and functionally [3]. The
chronology of the disease is adapted to lifetime, so
progression of osteosarcoma in dogs takes place in a
time frame (~2 years) that allows rapid assessment of risk,
prediction, and outcome [3]. The availability of detailedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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homology in sequence and gene order between both
species makes integration and extrapolation of genomic
data feasible [4,5].
We have previously identified sets of differentially
expressed genes that are associated with tumor behavior in
both canine and human osteosarcoma [6]. Specifically, we
characterized gene signatures that can stratify canine and
human osteosarcoma according to the predicted biological
behavior of the tumors [6]. The signatures are characte-
rized by increased cell cycle gene expression that regulate
G2/M transition and DNA damage genes in dogs with
worst outcomes. They are typified by increased expression
of ‘microenvironment interactions’ genes in dogs with
better outcomes. These patterns also were observed in
human osteosarcoma tumor datasets, but the mechanisms
responsible for generating these signatures have not yet
been fully defined.
MicroRNAs have potential uses in diagnosis and progno-
sis of tumors [7,8]. In our previous work, we used miRNA
profiles from over 300 human sarcoma samples included in
our S-MED database [www.oncomir.umn.edu] [9] to iden-
tify unique miRNA expression profiles for osteosarcoma.
Specifically, our data showed highly significant downregula-
tion of a large number of miRNAs at the 14q32 locus in
human osteosarcoma compared to normal bone tissue,
osteoblasts and other types of sarcomas [10]. In this
study, we demonstrate an inverse correlation between
the residual expression of 14q32 miRNA expression
and aggressive biological behavior in osteosarcoma
from humans and dogs.
Materials and methods
Human osteosarcoma tissue samples
Human tissues were obtained from two sources. Frozen
osteosarcoma tissue samples and normal bone samples
(femur/ tibia) of individuals from similar age groups
were obtained through the tissue procurement facility at
the University of Minnesota (Bionet). Demographic and
clinical information is provided in Additional file 1:
Table S1 and Additional file 2: Table S2. The excised
primary osteosarcoma tumors were obtained prior to
the initiation of chemotherapy or radiotherapy with
informed consent and following institutional review
board-approved protocols. Surgical resections were
subjected to standard clinical and histopathological
evaluation of hematoxylin and eosin (H&E) stained
sections. An additional 16 human osteosarcoma samples
with complete clinical follow-up information, including
outcomes, were obtained from Pancras C.W. Hogendoorn
with approval from the institutional review board in
compliance with the declaration of Helsinki. Demographic
and clinical information is provided for these samples in
Additional file 3: Table S3.Canine osteosarcoma tissue samples and cell lines
The procedures to obtain canine osteosarcoma samples
and establish corresponding explants and canine cell
lines have been described previously [6,11]. Briefly, naïve
(prior to treatment) samples were obtained from family-
owned pet dogs with stage I or stage II appendicular
osteosarcoma. Thirty-four of the 37 canine osteosarcoma
samples used in this study were derived from the primary
tumor in the leg. Samples OSCA-6 (Osteosarcoma Cells
ACCR-6), OSCA-11, and OSCA-16 were derived from
pulmonary metastases. Participation in the study required
the dogs’ owners to sign an informed consent form indica-
ting they understood the goals and procedures for this
study. Protocols and procedures were reviewed by the
appropriate Institutional Animal Care and Use Committee.
Samples were collected by attending veterinarians under
sterile conditions as part of a diagnostic biopsy procedure,
immediately after limb amputation, or at necropsy. Grossly
visible tumor was dissected from adjacent normal tissue,
rinsed in sterile phosphate buffered saline solution and
divided into three portions that were (1) fixed in 10%
neutral buffered formalin, (2) snap frozen, and (3) disaggre-
gated into single cell suspensions. Histologically, the cellular
composition of the resulting trimmed samples consisted of
>90% tumor cells. For the single cell suspensions, debris
was removed by passing sequentially through 500- and
200-μm mesh filters. Cells were then placed in a 4 cm2
culture dish at a density of 1 x 106/ml in 1 ml of DMEM
supplemented with 10% fetal bovine serum and cultured at
37°C in a 5% CO2 atmosphere. Cells were allowed to
reach ~80% confluence, at which time they were
passed to a 10-cm2 culture dish, and then again to a
25-cm2 culture flask. By the second passage, the cultures
were homogeneous and consisted of large polygonal to
plump spindloyd or slightly rounded cells. Histologic diag-
nosis of osteosarcoma was verified for all tumors from
formalin-fixed tissues. Osteoblastic origin of the cultured
cells was confirmed at the third passage by expression of
alkaline phosphatase and osteocalcin. As needed, cells were
maintained in culture using the same conditions described
above. Selected cell lines were tested after 30 passages in
culture and had no noticeable changes in morphology
or loss of alkaline phosphatase expression. These cell lines
are tumorigenic in vivo, and, when injected orthotopically
into nude mice, they have the capacity to metastasize
spontaneously to the lungs [12]. Demographic and
clinical information for the canine samples is provided in
Additional file 4: Table S4.
RNA isolation
Total RNA was isolated from 75–100 mg of frozen human
osteosarcoma tissue using the miRvana total RNA isolation
kit (Ambion Inc, Austin TX, USA) following the manufac-
turer’s protocol. RNA was quantified using the Nanodrop
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USA). Samples with RNA Index Number (RIN) values
of >6 were included in this study. Total RNA was isolated
from canine osteosarcoma tissue using TriPure Isolation
Reagent (Roche, Germany). The concentration of RNA
from canine osteosarcoma tissue was determined using
NanoDrop 1000 UV–vis spectrophotometer (NanoDrop
Technologies) and quality was assessed on a 1.2% formal-
dehyde agarose gel with ethidium bromide staining. RNA
from canine osteosarcoma cryopreserved cells was
isolated, quantified, and assessed for quality as previously
described [6].
Analysis of osteosarcoma mRNA and miRNA expression
Messenger RNA expression profiles from human tumors
were generated using the human HT-12 Beadchip
(Illumina Inc., San Diego, CA, USA) [13]. Human miRNA
expression profile datasets described previously (S-MED)
[9] were used in this study. Additional clinical information
relating to these samples is described in Additional file 1:
Tables S1 (human). Canine osteosarcoma mRNA gene
expression data generated on Affymetrix canine_2.0 arrays
were also used as previously described [6]. Complete
clinical and breed information for canine osteosarcoma
data is provided in Additional file 4: Table S4. miR-
NAs from the 14q32 cluster were mapped to the ca-
nine genome. Two miRNAs (miR-134 and miR-544)
that showed 100% conservation and mapped to the
predicted region of synteny in canine chromosome (CFA)
8 were used to examine expression of the 14q32 cluster in
dog samples (Additional file 5: Figure S1).
For human samples, mRNA data were assayed for quality
control as described [14]. Fluorescence values were
obtained from the Illumina detection system without back-
ground subtraction and were quantile normalized using
GeneData Expressionist Software (GeneData Inc, San
Francisco, CA, USA). Multiple probes to the same
gene product were then averaged to obtain a value
for each gene. The dataset was filtered to identify
genes with a variance >1 across the human osteosarcoma
tumor dataset and two normal bone samples. The mRNA
expression data were composed of human tumors and
normal bone samples which had been previously profiled
for miRNA expression levels, allowing us to directly calcu-
late Pearson correlation coefficients between miR-382 and
mRNA transcript levels. mRNAs that showed positive cor-
relation > 0.7 are listed in Additional file 6: Table S5, and
mRNAs that showed negative correlation are listed < −0.7
in Additional file 7: Table S6. These mRNAs and their
direction of change (increased for negative correlation and
decreased for positive correlation) were submitted to
Ingenuity Pathway Analyses to determine enriched func-
tions where the direction of change was consistent with
increased or decreased activity of enriched functions. Thequantile normalized human miRNA array data were first
filtered to determine miRNAs that showed variance >0.1
across the 15 human osteosarcoma tumors. Pearson corre-
lations were then calculated between all pairs of miRNA.
All pairs of miRNA with R2 >0.9 were then used to gene-
rate a correlation network visualization of the osteosarcoma
miRNAome. Pairwise Pearson correlations used to generate
Figure 1A are provided in additional file 8: Table S7.
Integrative analysis of human and canine gene and
miRNA expression data
Human genes that showed positive and negative correlation
to miR-382 were mapped to canine genes using gene sym-
bols. The direction of change was tracked using blue (nega-
tive correlation) and yellow (positive correlation) tags for
each gene so that the direction of change in the human
data could be observed in analogous fashion as previously
described osteosarcoma [6]. Unsupervised hierarchical
clustering was carried out with the Pearson correlation as
the metric using average linkage following log base 2
transformation of mean-centered data using Cluster3.0.
Heatmaps were generated from the CDT files generated
by Cluster3.0 using Java Treeview [15].
qRT-PCR
qRT-PCR of RNA from both human and canine osteosar-
coma samples was carried out using normalization to U6
snRNA. First strand cDNA was synthesized from total
RNA using a miScript reverse transcription kit (Qiagen,
Valencia, CA, USA). miRNA was quantified with an
miRscript SYBR Green PCR kit (Qiagen) using cDNA
equivalent of 50 ng total RNA per reaction. Mature
miRNA-specific forward primers provided in Table 1 were
purchased from Integrated DNA Technologies (Coralville,
IA, USA) and the universal reverse primer provided by the
manufacturer. Real-time PCR was performed at 55°C
annealing following standard protocol of the manufacturer
in 7500 Real Time PCR system (Applied Biosystems/Life
Technologies, Inc., Carlsbad, CA USA) and threshold cycles
(CT) were calculated using Sequence Detection Software
(SDS v1.2.1, Applied Biosystems). Relative gene expression
(expressed as fold difference relative to normal bone tissues
(human osteosarcoma) or relative to reactive osteoblasts
(canine osteosarcoma)) was calculated from the average of
triplicate CT value measurements using the 2-ΔΔCt
method [16] except for situations where the RNA available
was limited allowing only duplicate reactions to be carried
out. The standard error is represented as 2-(ΔΔCT ± SD).
Statistical analyses
Kaplan-Meier survival curves were generated with the
GeneData Analyst statistical package using the clinical data
provided in Additional file 3: Table S3 and Additional file 4:
Table 1 Oligos used for qRT-PCR analysis







Metastasis observed Metastasis observed
DC
BA
Osteosarcoma samples Osteosarcoma samples 
Osteosarcoma samples 
Figure 1 14q32 miRNA expression levels and metastasis in human osteosarcoma. (A) Correlation network of 14q32 miRNAs expression in
human osteosarcoma samples. Correlation network was constructed with Pearson correlation R >0.9 as the edges. The resulting correlation sub-
network contained thirty-six miRNAs and 33 of them mapped to the 14q32 locus. All pairwise correlations used to generate this image are given
in Additional file 8: Table S7. (B) Microarray based transcript levels of highly correlated 14q32 miRNAs in osteosarcoma tumors shown relative to
the level observed in FT-14 (human osteosarcoma primary tumor). miRNA profiling data from human osteosarcoma tumors where metastasis was
observed show stronger downregulation of 14q32 miRNAs (highlighted in red) than primary osteosarcoma tumors where metastasis was not
observed. (C) Microarray based transcript levels for miR-382 and miR-154. miR-382 and miR-154 show a high level of correlation (R2 = 0.95). (D)
qRT-PCR validation for miR-382 and miR-154 expression levels obtained in primary osteosarcoma tumors (FT-14, -7) where metastasis was not
observed and three primary osteosarcoma tumors with low levels of (FT-18, -13, -12) where metastasis was observed. miR-382 and miR-154 show
a high level of correlation (R2 = 0.99). Measurements were carried out in triplicate and were normalized to the expression levels in two
independent normal bone tissues that were also carried out in triplicate.
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online tool available at http://vassarstats.net/utest.html.
Results
14q32 miRNAs expression level decreases are highly
correlated in human osteosarcoma
Over 40 miRNAs are found to be present between the
imprinted genes DLK1 and DIO3 at the human 14q32 locus
[17]. We previously showed that these miRNA are signifi-
cantly downregulated in human osteosarcoma compared to
normal bone tissues [10]. We also showed that these
miRNA are downregulated in human osteosarcoma relative
to other types of sarcomas [9]. In order to verify that the
Sarver et al. Orphanet Journal of Rare Diseases 2013, 8:7 Page 5 of 11
http://www.ojrd.com/content/8/1/714q32 miRNA decreases in expression levels are
highly correlated in each of the individual tumor tissue
samples, we generated a correlation-based network using
the miRNA expression levels determined by array analyses.
The analysis revealed that miRNA expression levels found
at the 14q32 locus were highly correlated (Figure 1A and
Additional file 8: Table S7). The high correlation in expres-
sion levels suggests that an individual miRNA from this
locus could represent the expression levels of most of
14q32 miRNAs in osteosarcoma.
Magnitude of 14q32 miRNA decreases in human
osteosarcoma vary significantly
To demonstrate that the high level of correlation observed
for 14q32 miRNAs was derived from meaningful decreases
in expression levels, we plotted the expression levels of the
14q32 miRNA members in human osteosarcoma relative
to the human osteosarcoma primary tumor sample FT-14.
FT-14 showed a relatively high level of 14q32 miRNAs
(Figure 1B). Several of the osteosarcoma tumor samples
showed 14q32 miRNA levels similar to those observed in
FT-14 while several of the other osteosarcoma tumors
showed much more sizable decreases in 14q32 miRNAs.
The magnitude of miRNA expression decrease ranged
from ~3-fold to ~20-fold relative to the levels observed in
normal bone tissue by miRNA microarray analyses [9,10].
The heterogeneity in expression levels was seen in 14q32
locus miRNAs, and is specifically shown for two members
at this locus: miR-382 and miR-154 (Figure 1C). The
expression levels observed for miR-382 and miR-154
showed a high level of correlation (R2 = 0.95), exemplary of
the high correlations observed across the 14q32 miRNAs.
In order to confirm that the results obtained by miRNA
microarray for the magnitude of the 14q32 miRNA
decreases were meaningful, we carried out qRT-PCR for
miR-382 and miR-154. The results show that, relative to
normal bone, FT-14 and FT-7 exhibited a ~3 fold decrease
while FT-13, FT-18, and FT-12 showed much larger
~10- to 20-fold decreases in the expression levels of
these two 14q32 miRNAs (Figure 1D). The qRT-PCR
results for 14q32 miRNA correlation also showed
high correlation (R2 = 0.99) similar to the correlation
observed by microarray (R2 =0.95).
Correlations between 14q32 miRNA and mRNA
expression patterns predict association between
decreased 14q32 miRNA and human osteosarcoma
metastasis
To further understand the role of the 14q32 miRNAs in
human osteosarcoma, we profiled the mRNA transcript
levels of tumor samples for which we also had miRNA
profiles. We then determined mRNA that positively and
negatively correlated to miR-382. Since all the tested
14q32 miRNAs expression levels were highly correlatedon a sample-by-sample basis, we selected miR-382, as a
representative of 14q32 miRNAs. The results of this ana-
lysis in human osteosarcoma samples uncovered 288 and
97 genes that were positively (Additional file 6: Table S5)
and negatively (Additional file 7: Table S6) correlated,
respectively, to miR-382 expression (R2 > 0.7). All of these
385 genes and their direction of change in relation to
miR-382 are shown as a heatmap in Figure 2A. Ingenuity
Pathway Analysis (IPA) showed that genes involved in the
functional category ‘metastasis’ were enriched in this
signature (Enrichment p-value < 0.001 after Benjamini
Hochberg multiple testing correction). Furthermore, genes
of this signature in the functional category ‘metastasis’ were
predicted to have increased activity (Regulation Z-score
2.123) in osteosarcoma tumor samples that showed the
lowest levels of 14q32 miRNAs on the basis of the direction
of change of the correlated genes. This provides a potential
molecular rationale for the observation of metastasis being
present in the samples with the largest decreases in 14q32
miRNA transcript levels.
Gene expression levels correlated with 14q32 miRNAs
also predict poor survival in canine osteosarcoma
As a next step in comparative assessment, we mapped the
human osteosarcoma genes that positively and negatively
correlated with miRNA-382 (Figure 2A, direction of change
marked in yellow and blue) to orthologous canine genes
that were included in the Affymetrix canine 2.0 platform
(Figure 2B). Mapping of the human to canine genes pro-
vided 219 canine genes, which we then used to perform
unsupervised hierarchical clustering of the 26 canine
osteosarcoma samples. These 219 genes segregated the
canine osteosarcoma samples into two distinct branches.
Kaplan-Meier analysis using death as an outcome deter-
mined that there was a statistically significant (p < 0.05)
difference in survival between dogs in these two distinct
branches (Figure 2C). Dogs in which miR-382-positively
correlated mRNAs were expressed at lower levels and in
which miR-382-negatively correlated mRNAs were
expressed at higher levels had significantly shorter survival
times than the other group of dogs. This result shows that
genes that correlate with miR-382 are capable of showing
survival trends in dogs with osteosarcoma that are
consistent with our hypothesis in humans, thus inde-
pendently supporting a prognostic role for the 14q32
miRNA transcript level in osteosarcoma.
Expression levels of 14q32 miRNAs is inversely correlated
to metastasis in human osteosarcoma patients
Because metastasis genes are enriched in miR-382
correlated gene signature in canine osteosarcoma and
miR-382 expression levels showed potential prognostic
significance (ability to predict poor outcome) in the
































































Figure 2 Prognostic significance of genes correlated with 14q32 miRNAs in canine osteosarcoma. (A) Unsupervised clustering of human
mRNAs (n = 385) that shows high-level direct correlations to miR-382 for two normal bone tissues and 11 osteosarcoma tumors, for which we
have both mRNA profiles and miRNA profiles. A positive correlation to miR-382 is shown in yellow (n = 288), and a negative correlation to miR-
382 is shown in blue (n = 97), at the right of the heatmap. Directional Functional enrichment analyses (Ingenuity Pathways Analyses) shows that
correlating transcripts are enriched in transcripts involved in metastasis, and direction of change is consistent with increased activity of metastatic
function in tumors with decreased levels of 14q32 miRNA member, miR-382. Identities of positive and negatively correlating mRNA are provided
in Additional file 6: Table S5 and Additional file 7: Table S6. (B) Unsupervised hierarchical clustering heatmap of canine mRNA found in 26 canine
osteosarcoma-derived samples that correspond to human mRNAs correlating to miR-382. The yellow and blue bars represent correlations to
miR-382 (positive = yellow or negative = blue) observed in the human data indicating that the direction of change shows similar trends between
human and canine data.(C) Kaplan-Meier survival curves generated using the groups shown in 2B. Survival times are significantly different
between the two groups of tumors (p-value 0.02).
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ciation with outcomes. We analyzed the miRNA profiles
obtained from the initial cohort of human osteosarcoma
tumor tissue samples. Analysis revealed an interesting
inverse relationship: the osteosarcoma samples with thelowest levels of 14q32 miRNAs were from patients that
developed metastatic tumors (Figure 1B-D and 2A) This
human osteosarcoma sample cohort was incompletely
annotated (no survival data available), but a Mann Whitney






























































Figure 3 14q32 miRNA expression level, metastasis and
outcome in human osteosarcoma. (A) miR-382 expression levels
determined by qRT-PCR in osteosarcoma primary tumor samples
with clinical follow-up information. The miRNA expression levels
were normalized relative to normal bone tissues. Osteosarcoma
samples were ranked based on expression levels of miR-382 from
highest to lowest. Primary osteosarcoma patient samples that later
developed metastases are highlighted in red and samples from
patients who died due to disease are shown in black. Samples were
grouped based on whether they were above or below the median
expression level. (B) Kaplan-Meier analysis of metastasis in
osteosarcoma patients based on miR-382 expression. Group 1 and
Group 2 are significantly different (p-value 0.01). Patients with lowest
levels of miR-382 expression showed increased likelihood of
metastasis. (C) Kaplan-Meier analysis of survival in osteosarcoma
patients based on miR-382 expression. Group 1 and Group 2 are
different (p-value 0.08). Patients with lowest levels of miR-382
expression showed decreased likelihood of survival.
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(p-value 0.1357).Independent validation that 14q32 miRNAs are
prognostically significant in human osteosarcoma
To further examine the association between low 14q32
miRNA levels in osteosarcoma tumors and clinical out-
comes, we tested a representative 14q32 miRNA (miR-382)
in an independent set of primary tumor samples from 16
human osteosarcoma patients that had more robust clinical
follow-up annotation (Additional file 3: Table S3). As deter-
mined by qRT-PCR, all of the osteosarcoma tumor tissue
samples in this independent set showed lower levels of
miR-382 compared to normal bone tissues (Figure 3A). As
we noticed in the first human osteosarcoma dataset, the
lowest levels of miR-382 were found in primary osteosar-
coma tumors from patients where metastases and/or death
were later observed as follow-up. We further noticed that
there was a negative correlation between the levels of
miR-382 expression and patient survival (Figure 3A and see
Additional file 3: Table S3). To test whether lower levels of
14q32 were significantly associated with metastasis, we
used the Mann Whitney test. This test allowed us to reject
the null hypothesis that there was no association between
14q32 level and metastasis (p < 0.01).
Further, to examine the prognostic utility of the 14q32
miRNA level, we split the cohort into two groups based on
whether the miR-382 level was above the median value
(Group 1) or below the median value (Group 2). We
compared the two groups using Kaplan-Meier analyses
using both metastasis and death as outcomes (Figure 3B
and 3C). Human osteosarcoma tumor samples that had
the lowest levels of miR-382 were at higher risk for
metastasis (p-value 0.01) and showed a trend for death
(p-value 0.08) than patients with moderate miR-382
expression independently confirming the observation
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osteosarcoma.
Human 14q32 miRNAs are conserved and prognostically
significant in canine osteosarcoma
We examined the orthologous 14q32 locus miRNAs and
genes within the canine genome using the Entrez gene
database and were able to find them on CFA 8 (Additional
file 5: Figure S1). Similar to human 14q32 locus, canine
orthologous miRNAs were also found in the syntenic
region between genes DLK1 and DIO3. The order of the
miRNA is retained in the canine genome although differ-
ences in spacing were observed between human and canine
versions. Because we had observed systematic decreases in
human 14q32 miRNAs and the magnitude of the decrease
showed potential prognostic utility, we hypothesized that
the orthologous canine miRNAs on CFA 8 would also show
decreases in transcript level in canine osteosarcoma tumors
and that the magnitude of this decrease would show prog-
nostic utility. To address this, we determined the levels of
miR-544 and miR-134 (based on identical mature miRNA
sequences) in 16 canine osteosarcoma tumors from which
RNA was available by qRT-PCR (Figure 4A). In all 16 cases,
expression decreases were observed in the miRNA relative
to reactive canine osteoblasts. As observed in human osteo-
sarcoma the levels of miR-544 and miR-134 were directly
correlated (R2 = 0.88)
The canine osteosarcoma samples that were analyzed by
qRT-PCR were derived from dogs with overall survival
times ranging from 2 to 606 days with a median survival of
131.5 days (Additional file 4: Table S4). The canine cohort
was separated into two groups using the same method used
for the human tumor samples. Group 1 was composed of
tumor samples with miR-134 (Figure 4A) and miR-544
(Figure 4B) expression levels above the median survival
days and Group 2 was composed of tumor samples below
the median, and these two groups were interrogated via
Kaplan-Meier survival analysis (Figure 4D). Dogs with
tumor with lower levels of miR-134 had higher risk for
death (p-value 0.004) than dogs with tumors with higher
levels of miR-134 (Figure 4C). Similar results were obtained
using miR-544 expression levels (p-value 0.012, Figure 4D).
Together, these results indicate that the 14q32 miRNA
expression levels have prognostic utility in osteosarcoma,
a disease that shows conserved features between humans
and dogs.
Discussion
Molecular markers to identify osteosarcoma patients at risk
for metastatic progression are critical to adopting suitable
treatment options. Recently, several molecular markers
based on gene expression in tumor tissues have been iden-
tified in osteosarcoma. Higher levels of oncogene YY1
expression in primary sites of osteosarcoma are associatedwith metastasis and poor clinical outcomes [18]. Similarly,
overexpression of markers such as cancer-testis antigens,
Cystein Rich Protein (CYR61) and Melanoma Antigen
Family A (MAGEA) are implicated in predicting tumor
progression and prognosis in osteosarcoma [19,20]. Add-
itionally, the presence of tumor-infiltrating macrophages is
associated with metastasis suppression in high-grade osteo-
sarcoma [21]. These studies show that the development of
biomarkers for tumor progression and outcomes have
clinical significance and may help develop patient specific
treatment strategies. Recently, miRNAs from tumor tissues
have been proposed for use in the diagnosis, classification
and the prognosis of various cancers [22-26].
The cluster of miRNAs at the 14q32 locus show
decreased levels in human osteosarcoma [10]. miRNA
profiling of murine osteosarcoma tumors also show
decreases in the orthologuos region of chromosome 12
relative to the levels observed in normal bone tissues
(personal communication). Here, we report decreases in
miRNA in the orthologous region of CFA 8 cluster mem-
bers in canine osteosarcoma tumors. This is consistent
with the presence of a commonly conserved mechanism
of tumorigenesis involving the orthologous 14q32 locus
associated genes and miRNAs between these species.
Thus, the cross species comparison of human and canine
expression profiles provides an opportunity to define the
existence of evolutionarily conserved molecular signatures
and to determine whether those signatures influence the
outcome of our 3 patient cohorts (2 human and 1 canine).
In both the human and canine osteosarcoma cases the
14q32 miRNAs and its orthologs appear to be regulated
by a common mechanism, based on the high levels of
expression correlation observed between the transcript
levels of each member. Analyses of the Sarcoma MicroRNA
Expression Database (SMED) [9] data reveal that 14q32
miRNA, as a group, are lost in a subset of GIST (3/14) and
MFH (5/29). We conclude from this that the level of
14q32 miRNAs in general can be estimated from the
measurement of a single member of the family and
that measurement of the majority of the 14q32 miRNAs
would provide highly similar data. Polycistronic regulation
of these miRNAs has previously been proposed as a regula-
tory mechanism active at this locus and our data supports
this concept [17].
In an initial set of human osteosarcoma tumors
miRNA microarray profiling data we observed that lower
levels of 14q32 miRNA were associated with metastases.
We further validated this by qRT-PCR for both miR-382
and miR-154 for osteosarcoma tumors from this initial
dataset. We also showed that the lowest levels of miR-382
were significantly associated with metastasis and signifi-
cantly worse survival in a second independent set of
human primary osteosarcoma tumors where full clinical
follow-up information was available. Taken together, these
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Figure 4 14q32 orthologous region transcript levels and outcome in canine osteosarcoma. (A) miR-134 and B) miR-544 expression levels
determined by qRT-PCR in canine osteosarcoma primary tumor samples with clinical follow-up information. The miRNA expression levels were
normalized relative to reactive canine osteoblasts. Osteosarcoma samples were ranked based on expression levels of miR-134 from highest to
lowest. Samples were grouped based on whether they were above or below the median expression levels. (C and D) Kaplan-Meier analysis of
survival in osteosarcoma patients based on miR-134 and miR-544 expression. Survival of dogs with osteosarcoma in Group 1 and Group 2 are
significantly different (miR-134 p-value 0.004, miR-544 p-value 0.01). Dogs with lowest levels of miR-134 or miR-544 expression showed decreased
likelihood of survival.
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nostic utility for predicting the likelihood of developing
metastatic tumors and disease outcomes. This observation
is supported by three independent dataset from two diffe-
rent species. While the association between reduced
expression of 14q32 miRNAs and overall survival in
humans represented a trend, in dogs, the magnitudes of
miR-134 and miR-154 reduction were negative predictors
of survival. This is likely due to the fact that, unlike humans
(and especially children) where preserving life is the guiding
principle, companion animal patients are treated with
quality of life as the guiding principle. Therefore, metastatic
disease is seldom treated aggressively and recurrence often
leads to a decision of humane euthanasia, creating little
difference between the disease-free interval and overallsurvival [27]. It is prudent to note, however, that
osteosarcoma is a highly heterogeneous disease and
the sample sizes of the cohorts used in this study
were relatively small. Thus, our conclusion will require
additional validation in a larger cohort of osteosarcoma
patients with clinical follow-up.
We have previously shown that decreases in 14q32
miRNA levels stabilize cMYC expression in osteosarcoma
and subsequently increase the expression of oncogenic
miR-17-92 miRNAs [10]. Deregulations in 14q32
miRNA-cMYC network is also associated with increased
proliferation and apoptotic escape in osteosarcoma [10].
The prognostic relevance of decreasing 14q32 miRNA
levels may be explained 1) by increased activation of the
cMYC/miR-17-92 network leading to poor outcomes 2)
Sarver et al. Orphanet Journal of Rare Diseases 2013, 8:7 Page 10 of 11
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either directly or indirectly or 3) as a biomarker
whereby decreased levels of 14q32 miRNAs are observed
in osteosarcoma cases with poor outcomes.
Genes involved in metastasis are significantly enriched
in transcripts correlated to 14q32 miRNAs and the
direction of change indicates that metastasis function is
also significantly increased (Additional file 6: Table S5
and Additional file 7: Table S6). CDK5 and TWIST1
have been reported to increase metastasis [28,29] and
are upregulated in osteosarcoma tumors with low levels
of 14q32 miRNAs. IFNB1 [30], TEK [31] and COL18A1
[32,33] have been reported to decrease metastasis and
are downregulated in tumors with low levels of 14q32
miRNAs. We also noticed that TK1 is negatively corre-
lated to 14q32 miRNA levels. TK1 is involved in the
catalysis of phosphorylation of thymidine to deoxythymi-
dine monophosphate and expressed at high levels in pro-
liferating cells and appears to correlate with high risk in
multiple cancer types [34-36]. This suggests that genes
correlated with 14q32 miRNA expression patterns may
provides molecular rational for the observed association
between low levels of 14q32 and metastasis and poor sur-
vival outcomes and can be further investigated as markers
of prognosis.
We have previously demonstrated that comparative
studies of human and canine osteosarcoma patients
allow study of evolutionary conserved mechanisms of
tumorigenesis associated with outcomes [6]. A majority
of the dogs evaluated in this study (21/25 in the correlat-
ing miRNA analysis and 12/16 in the qRT-PCR analysis)
were treated with standard of care, which consists of
amputation of the limb to remove the primary tumor
followed by with adjuvant chemotherapy. Predictably,
treatment generally was associated with increased sur-
vival, but the negative correlation with miR-134 and
miR-154 was not driven by the type of treatment that
the dogs received, and in fact, the data suggest that
the dogs that received palliative care and amputation
(2, 8 and 58 days survival) would have been reasonable
candidates for more prolonged survival with standard of
care treatment.
Conclusions
We have identified and confirmed an association between
metastasis and 14q32 miRNA expression levels in human
osteosarcoma. Further, we have shown that the tran-
script decreases and prognostic significance for 14q32
miRNAs are conserved in canine osteosarcoma. Based
on these integrative, comparative, multi-species ana-
lyses, we conclude that larger decreases in 14q32
miRNA expression levels are associated with an
increased likelihood of metastases and poor outcomes
in osteosarcoma patients.Additional files
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